Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis [PDF]
Neuropsychopharmacology ReportsAim Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.
Yasufumi Nishii +4 more
doaj +5 more sources
Functional Pharmacological Validation of Betahistine Release from Chitosan Microspheres Using an Isolated Guinea-Pig Gastric Smooth-Muscle Model [PDF]
PharmaceuticsBackground: Betahistine-loaded chitosan microspheres have previously demonstrated formulation-dependent drug release; however, conventional in vitro release testing does not establish whether the drug incorporated into the delivery system retains ...
Bissera Pilicheva, Plamen Zagorchev
doaj +3 more sources
Pharmacokinetics and Dose Proportionality of Betahistine in Healthy Individuals
Scientia Pharmaceutica, 2020 Betahistine dihydrochloride is widely used to reduce the severity and frequency of vertigo attacks associated with Ménière’s disease.
Duaa Al-Tamimi
exaly +4 more sources
Combination Lorcaserin and Betahistine Treatment Improves Cognitive Dysfunction and Dopaminergic Neuron Activity in a Rat Model of Diet-Induced Obesity [PDF]
Brain SciencesBackground: Obesity is a complex disorder with both metabolic and neurocognitive consequences, including impairments in prefrontal cortex (PFC)-dependent learning and memory.
Ike de la Peña +2 more
doaj +3 more sources
Betahistine for residual dizziness after canalith repositioning in benign paroxysmal positional vertigo: a systematic review of randomized controlled trials [PDF]
Frontiers in PharmacologyBackgroundBenign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder. Although canalith repositioning maneuvers (CRMs) are highly effective, a substantial proportion of patients experience residual dizziness (RD) after ...
Esteban Ortiz-Prado +6 more
doaj +3 more sources
Efficacy of EGb 761 and Betahistine in Treatment of Dizziness/Vertigo: A Randomized Double-Blind Controlled Trial [PDF]
Journal of Otolaryngology - Head and Neck SurgeryImportance Dizziness/vertigo is a common symptom that can lead to falls and reduced confidence in daily activities. It can result from vestibular, non-vestibular, or unidentified etiologies. Effective treatments with minimal side effects are essential to
Narit Jianbunjongkit MD +2 more
doaj +3 more sources
Frontiers in Neurology, 2023 BackgroundBetahistine was registered in Europe in the 1970s and approved in more than 80 countries as a first-line treatment for Menière's disease. It has been administered to more than 150 million patients.
Michael Strupp +6 more
doaj +2 more sources
Frontiers in Neurology, 2018 This study is a pharmacokinetic (PK) and pharmacodynamics (PD) approach using betahistine doses levels in unilateral vestibular neurectomized cats (UVN) comparable to those used in humans for treating patients with Menière's disease.
Brahim Tighilet +2 more
exaly +3 more sources
Analysis of Benign Paroxysmal Positional Vertigo Cases in the Posterior Canal at a Tertiary Care Facility [PDF]
Journal of Pharmacy and Bioallied SciencesAim: The present study aims to evaluate the prevalence of posterior canal benign paroxysmal positional vertigo (BPPV) among all vertigo cases in a tertiary care hospital in India and assess the treatment outcomes of the Epley maneuver combined with ...
Megha Prabhakar +6 more
doaj +2 more sources
BETAHISTINE PREVENTS MEMORY LOSS IN PENTYLENETETRAZOLE-KINDLED MICE: THE ROLE OF ACETYLCHOLINESTERASE AND GLYCOGEN SYNTHASE KINASE-3β INHIBITION [PDF]
Zagazig University Medical Journal, 2023 Background: Recurrent seizures are usually associated with memory deficits. Objectives: This study assessed the effect of betahistine, histamine (H3) receptor antagonist, on memory deficits in pentylenetetrazole (PTZ)-kindled mice.
Ahmed Abdelsameea +2 more
doaj +1 more source